Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion type Assertion NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_head.
- NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion description "[Recent clinical trials showed that the sequential combination of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy could prolong the PFS and/or OS of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_provenance.
- NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion evidence source_evidence_literature NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_provenance.
- NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion SIO_000772 25474307 NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_provenance.
- NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion wasDerivedFrom befree-2016 NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_provenance.
- NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_assertion wasGeneratedBy ECO_0000203 NP1244795.RA7jrUCymw0svqliEu9qCJRuEgPLSEZPovsB2hO7TDaUw130_provenance.